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e �eld of neuroprotection generated consistent preclinical �ndings of mechanisms of cell death but these failed to be translated
into clinics. e approaches that combine the modulation of the inhibitory environment together with the promotion of intrinsic
axonal outgrowth needs further work before combined therapeutic strategies will be transferable to clinic trials. It is likely that
only when some answers have been found to these issues will our therapeutic eﬀorts meet our expectations. Stroke is a clinically
heterogeneous disease and combinatorial treatments require much greater work in pharmacological and toxicological testing.
Advances in genetics and results of the Whole Human Genome Project (HGP) provided new unknown information in relation
to stroke. Genetic factors are not the only determinants of responses to some diseases. It was recognized early on that “epigenetic”
factors were major players in the aetiology and progression of many diseases like stroke. e major players are microRNAs that
represent the best-characterized subclass of noncoding RNAs. Epigenetic mechanisms convert environmental conditions and
physiological stresses into long-term changes in gene expression and translation. Epigenetics in stroke are in their infancy but
oﬀer great promise for better understanding of stroke pathology and the potential viability of new strategies for its treatment.
1. Where AreWe?
e classical molecular targets for stroke include those in-
volved in oedema/in�ammation control, axonal regenera-
tion/plasticity, neurogenesis/angiogenesis, and events that
support recovery. For decades, old targets for stroke were
based on observations of molecular and cellular changes aer
stroke. Numerous in�ammatory markers, growth-associated
proteins, cell cycle proteins, NMDA receptors, molecules
involved in synaptic plasticity, dendritic branching, neu-
ral sprouting or extracellular matrix remodelling were key
targets. e �eld of neuroprotection generated consistent
preclinical �ndings of mechanisms of cell death but these
failed to be translated into clinical therapies. Many clinical
trials were carried out using doses that were already known
to be ineﬀective in preclinical trials, or employing time
delays outside the established therapeutic window. Some
trials were based on preclinical data showing relatively weak
eﬀects or those that were only established in one limited
model. Similar problems may occur in the �eld of neural
repair without careful work on the key points associated with
clinical translation [1]. e eﬀective delivery of neural repair
strategies is another major issue in recovery aer stroke.
Several growth factors and cytokines have been shown to
mediate neurogenesis and angiogenesis [2]. However these
are pleiotrophic molecules with likely multiorgan eﬀects
when delivered systemically. e �ne tuning of approaches
that combine the modulation of the inhibitory environment
together with the promotion of intrinsic axonal outgrowth
needs further experimental work before combined therapeu-
tic strategies will be transferable to clinic trials. It is likely
that only when some answers have been found to these
issues will our therapeutic eﬀorts meet our expectations [3].
Selective delivery systems, or more selective small molecules,
will need to be developed to minimize side-eﬀects in a neural
repair therapeutic. Nanomedicine is probably opening new
opportunities in this �eld as it may provide opportunities
to deliver larger quantities of drugs with the additional
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possibility to target therapeutics to speci�c brain regions
(superparamagnetic particles) and deliver to speci�c cell
types following antibody-mediated endocytosis [4].
Stroke is a clinically heterogeneous disease, with infarcts
commonly occurring in diﬀerent tissue compartments (white
matter and gray matter) and brain regions (basal ganglia,
cortex, thalamus, brainstem), and occurs most oen in aged
individuals. Combinatorial treatments require much greater
work in pharmacological and toxicological testing. Further,
treatments that promote anatomical rewiring will need to
be administered in combination with behavioural activity to
help “stamp in” patterns of brain rewiring that are adaptive
and to avoid the formation of maladaptive patterns of wiring.
A promising experimental treatment will need, at the very
least, to be tested in several diﬀerent rodent stroke models
and aged animals. Despite these issues, it is becoming clear
that the partial recovery that is commonly seen aer stroke
is associated with a reorganization of brain circuitry, and
those methods that can safely and eﬀectively enhance this
reorganization could potentially have great clinical value [5].
It is important to remember that all stroke patients exhibit
some degree of functional recovery. is process occurs
in a matter of days, continues most dramatically for the
�rst month in upper and lower extremity motor function
[6] and for up to a year in language and other cognitive
modalities [7, 8]. is recovery is only partial, leading to
the tremendous long-term personal and �nancial burdens of
this disease [9, 10]. What mediates natural neural repair in
stroke and what are the pharmacological targets to promote
improved recovery?Many of these processes of structural and
physiological change aer stroke have been correlated with
recovery but the causal mechanisms of neural repair in stroke
have not been de�ned. Axonal sprouting from the cortex
contralateral to an infarct into the cervical spinal cord and
brainstem ipsilateral to the infarct correlates with recovery of
forelimb use [11, 12]. Neurogenesis aer stroke is associated
with functional recovery, in that blocking mitotic activity
aer stroke reduces cognitive recovery [13]. e degree of
angiogenesis aer stroke in humans is correlated with the
level of recovery [14]. Stem cell, growth factor, and cytokine
therapies that promote functional recovery correlate with
increases in angiogenesis and neurogenesis near the infarct
[15, 16].
In recent years, the �eld of neural repair in stroke has
identi�ed cellular systems of reorganization and possible
new molecular mechanisms. However, conceptual barriers
now limit the generation of clinically useful agents. First,
it is not clear what the causal mechanisms of neural repair
are in stroke. Second, adequate delivery systems for neural
repair drugs failed and need to be determined for can-
didate molecules. ird, ad hoc applications of existing
pharmacological agents that enhance attention, mood, or
arousal to stroke were unsuccessful. New approaches that
speci�cally harness the molecular systems of learning and
memory provide a new avenue for stroke repair drugs.
Fourth, combinatorial treatments for neural repair need to
be considered for clinical therapies. Finally, neural repair
therapies have as a goal altering brain connections, that is,
rewiring cognitive maps and active neural networks. ese
actions may also trigger a unique set of “neural repair side
eﬀects” that need to be considered in planning clinical trials
[17]. Future research will be needed to address the above
limitations in this �eld and problems in translation from the
basic science to poststroke clinics.
2. Heading towards the XXII Century
eWhole Human Genome Project (HGP) early in the XXI
century ushered in a wave of optimism and anticipation
that new therapies and even cures for many diseases would
soon be forthcoming [18]. Aside from impressive progress in
reducing the costs of genotyping [19], the promise oﬀered by
the HGP has been largely unrealized, particularly in relation
to stroke [20]. More than 100 Genome-Wide Association
studies [21] made possible with the new information pro-
vided by the HGP have yielded many interesting �ndings
about the genetics of stroke-related brain injury, but all have
generally fallen far short of identifying a genetic basis for
vulnerability to cerebral ischemia [22]. With the notable
exception of monogenic diseases, genome-wide association
studies (GWAS) have generally not been an eﬃcient strategy
to elucidate the genetic mechanisms of disease, particularly
in complex pathologies such as ischemic cerebral injury [23].
ese studies have taught us that most disease pathologies,
including those associated with cerebral ischemia, are poly-
genic and involve highly variable contributions from the
genes involved. Such �ndings raise the important question�
why are the genetic components of complex diseases so
variable? Polygenomic pathology as well as individual gene
variability contributes to stroke as described in many GWAS.
Long before the HGP was completed, it was recognized that
genetic factors were not the only, or perhaps even not the
most important, determinants of responses to some diseases.
It was recognized early on that “epigenetic” factors were
major players in the aetiology and progression of many dis-
eases [24]. Following completion of the HGP, understanding
of epigenetic mechanisms has expanded rapidly, and it is now
recognized that epigenetic regulation involves three main
categories of mechanisms [25, 26], that is, DNA methyla-
tion that attenuates gene expression; enzymes that add and
remove acetyl groups to lysine residues in histone proteins
and thereby facilitate or inhibit their dissociation for DNA
with subsequent increases or decreases in gene expression,
respectively; and the pathways that regulate the synthesis and
action of micro-RNAs (miRNAs) that regulate mRNA trans-
lation. MicroRNAs represent the best-characterized subclass
of ncRNAs. Together, these epigenetic mechanisms convert
environmental conditions and physiological stresses into
long-term changes in gene expression and translation. In
contrast to DNA methylation and histone modi�cation, the
main function of miRNAs is associated mainly with message
translation rather than with gene transcription. e miRNA
molecules directly bindmRNA and either retard or accelerate
its degradation. In addition, miRNA binding to mRNA
can block message translation [27]. e sequences coding
for miRNAs oen arise from intronic DNA and regulate
the gene products coded by adjacent exons. More than
1,000 unique sequences of miRNA have been identi�ed, and
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together these regulate approximately 30% of all mammalian
genes [27]. A single miRNA can help regulate multiple
diﬀerent gene products, and a single gene product can be
regulated by multiple diﬀerent miRNAs. As such, miRNAs
play key roles in many cellular functions and are particularly
important in cardiovascular biology [28–33]. Expression and
action of miRNAs change with development and in response
to nutritional stress [34]. e actions of speci�c miRNA
molecules can be inhibited by reverse-sense antagomirs,
and these have proven useful in many studies of miRNA
function [35, 36].
3. The RNAMachine
RNAs are an integral component of chromosomes and
contribute to their structural organization [37, 38]. It is
now becoming apparent that chromatin architecture and
epigenetic memory are regulated by RNA-directed pro-
cesses where, although the exact mechanisms are yet to be
understood, involve the recruitment of histone modifying
complexes and DNA methyltransferases to speci�c loci [39].
Whereas long nonprotein coding RNAs (ncRNAs) have been
classically implicated in the regulation of dosage compen-
sation and genomic imprinting in animals [40], they seem
to play a much broader role in the epigenetic control of
developmental trajectories [39]. For example, ncRNAs may
repress gene expression and be associated with complex
epigenetic phenomena [41, 42]. Small ncRNAs have been
consistently linked with heterochromatin formation via the
process of RNA interference (RNAi). Higher-level nuclear
organization and chromosome dynamics are also regulated
by ncRNAs in a variety of systems. ese �ndings reveal
RNA-based mechanistic links between these processes in
mitosis. e RNAi pathway along with directed histone
modi�cations also regulates the organization of the nucle-
olus [43, 44]. In mammals, transcription of long ncRNAs
contributes to various processes including T cell receptor
recombination [42], maintenance of telomeres [45, 46],
X-chromosome pairing required for dosage compensation
[47], and inactive X-chromosome perinucleolar localization
[48]. e functional organization of chromatin can also
be regulated by ncRNAs derived from repetitive elements.
Given the abundance of transcribed repetitive sequences,
this may represent a genome-wide strategy for the control
of chromatin domains that may be conserved throughout
eukaryotes. Moreover, such observations and others sug-
gest that a large portion of the genome may in fact be
functionally active and that transposon-derived sequences
may not be reliable indices of the rate of neutral evolution
[49].
4. AWorld of Noncoding RNAs
e examples above provide proof-of-principle that RNA
can regulate gene expression at many levels and by using a
wide array of mechanisms. e ENCODE project showed
that at least 93% of analyzed human genome nucleotides
are transcribed in diﬀerent cells, with similar �ndings in
mice and other eukaryotes, which indicate that there may be
a vast reservoir of biologically meaningful RNAs that could
greatly exceed the ∼1.2% encoding proteins. A fraction of
RNAs with short open reading frames (ORFs) potentially
encodes peptides but on the other side of the ledger many
currently annotatedORFs are not conserved andmay be false,
which could reduce the number of protein-coding genes in
the human genome. ere has been debate about whether
these ncRNAs are (in the main) functional or simply noise.
In some cases, it may be the transcript or merely the act of
transcription, or both, that are relevant. Nevertheless, many
observations indicate that substantial numbers of ncRNAs are
intrinsically functional. ese include the fact that many loci
produce spliced (and alternatively spliced) transcripts that
are developmentally regulated. A large fraction of ncRNAs
are expressed in speci�c regions of the brain, exhibiting
precise cellular locations. Some mark new domains within
the cell, which means that ncRNAs are also set to have a
major impact in cell biology. Comparative analyses indicate
that ncRNA promoters are, on average, more conserved than
those of protein-coding genes and that ncRNA sequences,
secondary structures, and splice site motifs have been subject
to purifying selection. Moreover, many ncRNAs are evolving
quickly, and some have undergone recent positive selection,
as exempli�ed by HAR1 RNA expressed in the human
brain, which contains the sequence conserved in mammals
that most rapidly diverged aer the human-chimpanzee
separation. Although the need for large-scale approaches to
explore the function of ncRNAs is evident, a glance at the
genome browser will show noncoding expressed sequence
tags associated with most genes of interest that may have
regulatory functions. ncRNAs are already being identi�ed
as markers for cancer and associated with other complex
diseases such as coronary disease, diabetes, and Alzheimer’s.
e elucidation of their functionmay signi�cantly contribute
to the understanding and treatment of such conditions.
It may also transform our understanding of the genetic
programming of multicellular organisms, particularly as it
appears that regulation dominates the information content of
complex systems [49].
5. RNA-Based Epigenetic Mechanisms
Implicated in Stroke
e predisposition to and the development of cerebrovas-
cular diseases involves the dynamic interplay between envi-
ronmental and intrinsic vascular, systemic, and CNS risk
factors. Increasing evidence suggests that disruption of these
homeostatic and plasticity events involves an array of deregu-
lated epigenetic processes [50]. Appreciation of the potential
involvement of epigenetic mechanisms in the incidences and
outcomes of stroke has begun to motivate studies of these
mechanisms in relation to cerebral ischemia and stroke. DNA
methylation has been suggested to contribute to delayed
ischemic brain injury in mice and has been correlated with
stroke risk in humans. Histone modi�cations have been
implicated in ��S-induced cerebral in�ammation and oxida-
tive neuronal injury and may be neuroprotective following
ischemia in rodent brains [17].
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6. ncRNAs and RNA Regulatory Networks
e most recently recognized category of epigenetic mech-
anisms includes the pathways involved in the transcription,
processing, and action of a class of short (≈20–25 nucleotides)
RNA molecules identi�ed as micro-RNAs (miRNAs) [51].
MicroRNAs are �rst transcribed as longer primary miRNA
transcripts that can have multiple functional miRNAs
embedded within a single transcript.ese primary miRNAs
are processed to form mature molecules of approximately
22 nucleotides that regulate the expression of large numbers
of target genes through sequence-speci�c interactions with
messenger RNA (mRNA) molecules. MicroRNAs bind to
the 3 regulatory regions and to particular coding regions of
their cognate mRNAs, leading to sequestration for storage
or degradation and to translational repression. Cerebral
ischemia in animal models is associated with highly selective
and temporally regulated pro�les of miRNAs in the postis-
chemic brain [52]. Diﬀerential expression of miRNAs in
the postischemic brain correlates with diﬀerential expression
of their target mRNAs, including many implicated in tran-
scriptional regulation, ionic �ux, in�ammation, and other
stress responses. ese results suggest that miRNA networks
regulate a spectrum of processes in the postischemic brain.
MicroRNA-140 is one of the miRNAs that was rapidly
up regulated in the brain 3 hours aer middle cerebral
artery occlusion and sustained for 72 hours. One of the
validated target mRNAs for miRNA-140 encodes stromal
cell-derived factor 1, which plays an important role in the
CNS by mediating neural progenitor cell proliferation and
migration and tissue repair aer cerebral ischemia [53]. is
observation suggests that miRNA-140 may be responsible,
in part, for mitigating the regenerative response in the
postischemic brain. Furthermore, some miRNAs that are
highly diﬀerentially expressed in brain tissue can similarly
be detected in peripheral blood [54], suggesting not only
that these may serve as novel clinical biomarkers but also
that these miRNAs may be involved in mediating systemic
responses to cerebral ischemia.
Multipotent mesenchymal stromal cells (MSCs) have
potential therapeutic bene�t for the treatment of neurological
diseases and injury. MSCs interact with and alter brain
parenchymal cells by direct cell-cell communication and/or
by indirect secretion of factors and thereby promote func-
tional recovery. In another study, using Multipotent mes-
enchymal stromal cells (MSCs) treatment of rats subjected
to middle cerebral artery occlusion (MCAo) signi�cantly
increased microRNA 133b (miR-133b) level in the ipsilateral
hemisphere. In vitro, cultured neurons treated with exosome-
enriched fractions from MSCs exposed to MCAo brain
extracts signi�cantly increased the neurite branch number
and total neurite length.is study provides the �rst demon-
stration that MSCs communicate with brain parenchymal
cells and may regulate neurite outgrowth by transfer of miR-
133b to neural cells via exosomes [55].
Further, microRNAs (miRNAs) regulate formation of
myelinating oligodendrocytes. Overexpression of miR-219
and miR-338 as oligodendrocyte-speci�c miRNAs is suf-
�cient to promote oligodendrocyte diﬀerentiation. ese
�ndings illustrate that miRNAs are important regulators of
oligodendrocyte diﬀerentiation, providing new targets for
myelin repair [56].
Long ncRNAs represent another important and emerging
subclass of ncRNAs that may also play a role in stroke. Long
ncRNAs have roles in local and long-range chromatin remod-
elling, transcriptional regulation, and alternative splicing and
other forms of post transcriptional RNA processing [57].
ey are implicated in the development of axonal and den-
dritic connections and synaptic modulation associated with
neural network plasticity. Long ncRNAs may also participate
in the generation of the long-term potentiation that underlies
learning andmemory [58]. An lncRNA can bind to the cyclin
D1 gene, a critical mediator of ischemic neuronal cell death
[59]. ANRIL (NCBI EntrezGene 100048912) is an lncRNA
with an unknown function that is associated with the devel-
opment of atherosclerosis, diabetes, and aneurysms, possibly
through eﬀects on vascular smooth-muscle proliferation and
migration.GOMAFU (NCBI Entrez Gene 440823) is another
lncRNA that is expressed in the nucleus of developing neural
cells. Although the function of GOMAFU is unknown, a
case-control association study identi�ed a single nucleotide
polymorphism associated with the GOMAFU locus as a sus-
ceptibility factor for cardiovascular disease [60]. In addition
to miRNAs and lncRNAs, other ncRNA transcripts, such as
those resembling the virus-like 30 family of interspersed,
repeated, mobile genetic elements (i.e., retrotransposons),
are also increased in mouse brain aer cerebral ischemia.
ese virus-like 30 ncRNAs are induced by ischemia and
paradoxically bound to polyribosomes, although they are not
translated. e distribution of these virus 30-like ncRNAs
in ribosomal fractions is distinct from the distribution of
mRNAs that are translated or translationally repressed and
suggests a novel structural or catalytic role for these ncRNAs.
Together, these observations imply that the expression and
function of several newly identi�ed subclasses of ncRNAs
may be associated with the pathogenesis of stroke [61].
Figure 1 represents biogenesis of microRNAs.
7. RNA Editing and DNA Recoding in Stroke
is process is intimately linked with ncRNA expression
and is another epigenetic process, RNA editing, a mecha-
nism for altering nucleotides in RNA molecules that allows
the generation of signi�cant diversity of transcripts in a
highly environmental-responsive manner. In transient global
cerebral ischemia models, the death of hippocampal CA1
pyramidal neurons is mediated by selective downregulation
of an RNA-editing enzyme leading to defective editing of
the ionotropic glutamatergic -amino-3-hydroxy-5-methyl-
4-isoxazole-propionic acid GluR2 receptor subunit, which
in�uences the vulnerability of hippocampalCA1 pyramidal
neurons to ischemia-associated cell death [62]. By alteration
of RNA nucleotides, not only does editing have the capacity
to change amino acids and modulate splice-site choice in
protein-coding transcripts, but it also has roles in ncRNA-
related processes such as miRNA localization, target diver-
si�cation, and function [63]. MicroRNA regulatory network
dynamics mediated by RNA editing may be implicated in
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stroke. For example, miRNA-151 is found in neurons and
up-regulated aer middle cerebral artery occlusion, and the
immature form of miRNA-151 (primary miRNA-151) is
subject to RNA editing that in�uences processing of the
primary miRNA into mature miRNA within the CNS [64].
Intriguingly, miRNA-151 is thought to target various cell
cycle regulators as well as protein tyrosine kinase 2 (focal
adhesion kinase), a nonreceptor tyrosine kinase involved
in integrin and growth factor signalling pathways that is
diﬀerentially regulated aer middle cerebral artery occlusion
and implicated in modulating neurite outgrowth, neuronal
plasticity, and restoration of neural network integrity within
the ischemic penumbra [65]. ese observations imply that
multiple layers of interleaved epigenetic controls that include
RNA editing andmiRNA regulatory networks are involved in
stroke. Another, miR120 is positively correlated with better
prognosis in stroke patients and antagonists to miR497,
infused prior to stroke, reduce infarct volume. However, to
date, no neuroprotective miRNAmimics or antagomirs have
been identi�ed that are eﬀective when delivered poststroke.
To identify neuroprotectivemiRNAs, Selvamani et al. studied
a known neuroprotectant, Insulin-like Growth Factor (IGF-)
1, for speci�c miRNA target sites, with the goal of inhibiting
these miRNA to elevate local levels of IGF-1 poststroke. IGF-
1 is a critical endogenous neuroprotectant and low normal
levels of peptide hormone are associated with increased
morbidity andmortality in ischemic heart disease and stroke.
Exogenous IGF-1 reduces ischemic injury in many species,
stimulates stroke induced neurogenesis and promotes neu-
ronal survival, neuronal myelination, and angiogenesis. Two
conserved IGF pathway regulatory microRNAs, Let7f and
miR1, can be inhibited to mimic and even extend the
neuroprotection aﬀorded by IGF-1. Collectively these data
support a novel miRNA-based therapeutic strategy for neu-
roprotection following stroke in experimental model [66].
In addition, the apolipoprotein-B-(ApoB-) editing cat-
alytic subunit (APOBEC) family of RNA editing and DNA
recoding enzymes may also play a role in stroke. ese
enzymes are cytidine deaminases that edit (deoxy)-cytidine
to (deoxy)-uridine and act on RNA and DNA molecules
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[67]. One of the substrates for these enzymes is APOB
(NCBI Entrez Gene 338) mRNA, which encodes an impor-
tant apolipoprotein found in chylomicrons and low-density
lipoproteins. Mutations of the APOB gene and its regulatory
region cause dyslipidemias (eg hypobetalipoproteinemia and
hypercholesterolemia), and genetic variants of APOBEC1
and APOBEC2 are associated with high levels of serum low-
density lipoproteins and increased atherosclerosis [68]. e
APOBECs may aﬀect stroke risk through eﬀects on APOB
mRNAediting; however, APOBECsmay play additional roles
within the brain. APOBEC-mediated DNA recoding protects
the stability of the genome and also enhances its diversity and
plasticity [64]. Although these functions have largely been
characterized within the immune system, it is intriguing that
the APOBEC3 enzyme subfamily has signi�cantly expanded
in primates and that certain members (i.e., APOBEC3G)
are expressed in postmitotic neurons [69]. Furthermore,
accumulating evidence suggests that RNA editing and DNA
recoding may be functionally linked through speci�c classes
of reverse transcriptases within the CNS that can medi-
ate RNA-directed DNA modi�cations [70]. Also, like the
immune system, the CNS exhibits exquisite degrees of func-
tional plasticity by modulating cell identity and connectivity.
Because of these observations, we have previously suggested
that DNA recoding in the brain might represent a novel
mechanism for transmitting productive RNA editing events
back into the postmitotic neuronal genome [61].
is suggests a possible evolutionary mechanism to
account for the multigenerational inheritance of complex
cognitive and behavioural traits and risk pro�les for stroke
in response to both productive and adverse environmental
events. Apart from the molecular mechanisms responsible
for epigenetic regulation, a broad variety of evidence has
implicated epigenetic regulation in long-term environmental
in�uences on gene regulation. One of the best-known such
examples is the epidemiological work of Pearce, who identi-
�ed a cohort of Dutch individuals with a uniquely elevated
risk of coronary artery disease [17]. e common feature
among this cohort was maternal food restriction during the
Dutch famine inWorldWar II.ese early studies established
that foetal nutritional stress could produce life-long changes
in the vulnerability to cardiovascular disease, and subsequent
work has further established the epigenetic basis of such “vas-
cular programming”. Similarly, other studies have implicated
epigenetic mechanisms in long-term responses to hypoxia
[71–74] and ischemia [75–78]. Of particular relevance to
stroke are �ndings that miRNA is involved in ischemic
preconditioning [79] and may even play a role in ischemic
post conditioning. Together, these results emphasize that
environmental in�uences can produce long-term changes in
physiological patterns of gene expression through epigenetic
mechanisms.
8. Epigenetics and Transient Ischemia
Transient global cerebral ischemia (TGCI) following sys-
temic hypoperfusion is associated with selective and delayed
death of hippocampal CA1 pyramidal neurons through the
mediation of a series of parallel epigenetic processes. Within
vulnerable neurons, there is selective downregulation of
ADAR2 and defective Q/R site editing of the ionotropic
glutamatergic AMPA, GluR2 receptor subunit, resulting in
the expression of the death-promoting calcium permeable
GluR2 isoform and associated impairment in GluR2 mRNA
and protein expression, receptor assembly, membrane traf-
�cking, and synaptic targeting. Heterogeneity in ADAR2-
mediated GluR2 Q/R site editing enhances the vulnerability
of hippocampal CA1 pyramidal neurons to global ischemia-
associated neurodegeneration. In parallel, TGCI induces the
selective expression of RESTwithin these vulnerable neurons
with associated suppression of GluR2 and the CA1- selective
m-opioid receptor 1 (MOR1) in inhibitory interneurons
through a series of histone modi�cations, including MOR1
promoter H3/4 deacetylation, H3K9 dimethylation and asso-
ciated recruitment of the G9a histonemethyltransferase.is
has been postulated to represent a failed attempt of inhibitory
interneurons to dampen the excitotoxicity of CA1 pyramidal
neurons by disinhibiting GABA release. Ischemia-induced
alterations in the histone code may be the result of early
dephosphorylation and inactivation of components of the
neuronal ERK1 and CREB1 signal transduction pathways
that simultaneously reduce expression of the antiapoptotic,
bcl2 gene and activate expression of the proapoptotic,
caspase-3 eﬀector pathway [80–83].
ere is also evidence that the more common type of
focal stroke syndrome due to occlusion of themiddle cerebral
artery is associated with aberrant DNA methylation and
histone H3 deacetylation, and that systemic administration
of a potent HDAC inhibitor reduces the volume of the
ischemic infarction whereas concurrent application of an
HDAC inhibitor with a DNA demethylating agent confers
neuroprotection against mild but not severe ischemic injury
[84]. Increasing evidence suggests that intricate epigenetic
processes may also operate to modulate premorbid vascular
pathology and responses to agents that attenuate ischemic
risk factors. For example, a novel deubiquinating enzyme,
ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), mutated
in a rare inherited form of Parkinson’s disease, is normally
present in vascular endothelial cells of atherosclerotic lesions
of human carotid arteries and attenuates pathological vascu-
lar remodeling by inhibiting tumor necrosis factor a-induced
NF-kappaB activation [85]. Interestingly, the normal balance
of transcriptional activity and associated histone acetyla-
tion and methylation that is disrupted in cerebral ischemia
depends, in part, on maintenance of the balance of histone
H2A andH2Bmono-ubiquitylation that is mediated through
the actions of UCHL1 [86]. Moreover, statins have recently
been shown to act through inhibition of HDAC activ-
ity and associated enhancement of histone H3 acetylation
[87].
Transient focal ischemia in adult rat brain regulates the
expression of microRNAs predicted to target proteins known
to mediate in�ammation, transcription, neuroprotection,
receptor function, and ionic homeostasis in the brain. e
mRNA levels for proteins important tomicroRNA biogenesis
pathways, including Drosha, Dicer, the cofactor Pasha, and
the precursor microRNA transporter Exportin 5, were not
altered aer transient ischemia. However, transient ischemia
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repressed miR-145 expression, which resulted in increased
translation of its mRNA target, superoxide dismutase-2, in
post-ischemic adult rat brain. It is interesting to note that in
silico studies revealed eight microRNAs induced by transient
ischemia with complementarity to 877 gene promoters, sug-
gesting that microRNAs also regulate gene expression [88].
ere is also speci�c induction of miR-497 in mouse brain
aer transient ischemia, and in mouse N2A neuroblastoma
(N2A) cells aer oxygen-glucose deprivation [86]. Levels
of miR-497 correlated with oxygen-glucose deprivation-
induced eﬀects on N2A cells: decreased miR-497 suppressed
cell death, whereas increased miR-497 increased neuronal
loss. As miR-497 directly binds to the 30-UTR of Bcl-2/-
w, the knockdown of cerebral miR-497 in mice enhanced
Bcl-2/-w protein levels in the ischemic region, attenuated
brain infarction, and improved neurological outcome aer
focal ischemia. ese studies show that miR-497 promotes
ischemic neuronal death by repressing expression of Bcl-2
and Bcl-w, supporting the role of apoptosis in the pathogen-
esis of ischemic brain injury [89, 90].
9. Molecular Studies of MicroRNAs in
Human Stroke
Whole genome expression microarrays can be used to study
gene expression in blood, which comes in part from leuko-
cytes, immature platelets, and red blood cells. Since these cells
are important in the pathogenesis of stroke, RNA provides
an index of these cellular responses to stroke. Human studies
show gene expression changes following ischemic stroke.
ese gene pro�les predicted the cause of stroke in 58% of
cryptogenic patients. New techniques to measure all coding
and noncoding RNAs along with alternatively spliced tran-
scripts will markedly advance molecular studies of human
stroke [91].
Platelets are crucial for the maintenance of haemostasis
and contribute to thrombosis and vessel occlusion that
underlies stroke and acute coronary syndromes. Although
platelets are anucleate, they do contain mRNAs and are
capable of protein synthesis [89]. Human platelets have been
shown to contain microRNAs and Dicer in Ago2 protein
complexes, as well as mRNA for the P2Y purinoceptor 12
that is involved in platelet aggregation, suggesting a role for
microRNAs in this system [92].
Mutations in mitochondrial DNA are responsible for a
spectrum of mitochondrial encephalomyopathies, including
mitochondrial encephalopathywith lactic acidosis and stroke
like episodes. Although the DNA sequences that harbor
these mutations generally do not code for proteins, many
of them encode transfer (tRNAs) and ribosomal RNAs
(rRNAs). e array of clinical symptoms seen in mito-
chondrial disorders highlights the functional importance
of nonprotein-coding RNAs (ncRNAs) such as tRNAs and
rRNAs that are transcribed from nonprotein-coding DNA
sequences. In fact, the pathogenesis of a spectrum of neu-
rodevelopmental, neurodegenerative, and neuropsychiatric
diseases is increasingly being associated with mutations of
ncRNAs [61].
10. MicroRNAs as Novel Biomarkers in
Brain Ischemia
ebrain is a conspicuous consumer of energy resources, and
a major consequence of cerebral ischemia is the disruption
of energy metabolism and exhaustion of adenosine triphos-
phate. Because RNA can rapidly be activated, modi�ed,
transported, and degraded, it serves as a highly �exible, high
�delity, information encoding, and functional molecule. e
ability of RNAmolecules to dynamically store, transform, and
transmit both “digital” and “analogue” information is a key
feature of RNA-based systems [61].
Studies support the potential for microRNAs as novel
biomarkers for vascular injury and diseases. Expression
pro�ling of microRNAs in ischemic rat brains revealed
signi�cant changes in several micro-RNAs, and some of
the microRNAs highly expressed in ischemic brain were
detected in blood samples [93]. Peripheral blood examined
in ischemic stroke patients revealed diﬀerential expression
of microRNAs implicated in endothelial cell and vascular
function, erythropoiesis, angiogenesis, neural function, and
hypoxia, and altered microRNAs were detectable even sev-
eral months aer the onset of stroke [94]. Rat models of
ischemia, brain haemorrhage, and kainate-induced seizures
also revealed regulated expression of microRNAs in hip-
pocampus and blood in each treatment group,many of which
changed >1.5-fold in both tissues [95].
Evidence also suggests that microRNAs serve as eﬀec-
tors in neointimal lesion formation, and in angiogenesis in
normal and injured brain. e miR-17–92 cluster is highly
expressed in human endothelial cells and miR-92a, a compo-
nent of this cluster, targets several mRNAs for proangiogenic
proteins. Overexpression of miR-92a in endothelial cells
blocked angiogenesis, and systemic administration of an
miR-92a antagomir led to enhanced blood vessel growth and
functional recovery of damaged tissue in mouse models of
limb ischemia and myocardial infarction [93]. In a similar
vein, pro�ling of microRNAs in vascular walls aer balloon
injury revealed that miR-21 is overexpressed in injured vas-
cular tissue, and that miR-21 depletion inhibited formation
of neointimal lesions. Depletion of miR-21 decreased cell
proliferation and increased cell apoptosis, and targets of
miR-21 include the phosphatase and tensin homolog protein
(PTEN) and Bcl-2 [96].
11. The Era of EpigenomicMedicine
For treatment of stroke, RNA-based therapies and addi-
tional epigenetic strategies are extremely promising. Indeed,
approaches for gene silencing that use short regulatory
ncRNAs, including miRNAs and related short interfering
RNAs (RNA interference) have already been used to identify
new molecular targets for treating stroke, such as Bcl-
2 and 19-kDa interacting protein 3 [97] and carboxyter-
minalmodulator protein [98]; however, RNA interference-
based gene silencing for treating stroke has yet to advance
beyond preliminary studies. erapeutic approaches using
other customized oligonucleotides are also being developed
formodulation of endogenous RNA transcripts. For example,
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novel antisense oligonucleotides have now been constructed
with the capacity to repair and reprogram aberrant disease-
associated RNAs. e mechanism of action of these agents
includes alteration of pre mRNA processing (e.g., alternative
splicing) and promotion of trans-splicing, which results in
the creation of a composite mRNA from 2 separate pre-
mRNAs [99]. Although RNA-based approaches such as these
are still in their infancy, they oﬀer the potential for dynamic
and highly selective reprogramming of gene expression and
function. Because of their unique properties, functional
RNA molecules may be ideal candidates for a number of
future therapeutic strategies. For example, through sequence-
speci�c digital interactions with DNA, RNA-based therapeu-
tic molecules may serve as guideposts for a certain genomic
sequence. rough analog interactions with proteins, RNAs
may also act as molecular beacons for recruitment of DNA
methylation and histone-modifying enzyme complexes to a
given genomic locus. us, multifunctional RNA molecules
with binding domains for DNA and for these enzyme com-
plexes may be used for targeting epigenetic modi�cations
to a single gene locus or to multiple gene loci that harbour
a shared genomic sequence. Furthermore, because RNA
molecules can interact with DNA, RNAs, proteins, and small
molecules, RNA-based therapeutics may also provide the
�exibility and speci�city necessary to selectively manipulate
intricate pro�les of gene transcription, posttranscriptional
RNA processing, and translation by targeting epigenetic
eﬀectors such as nucleosome- and chromatin-remodeling
complexes, multiple ncRNAs (e.g., miRNAs and lncRNAs),
and RNA editing and DNA recoding enzymes. Although
these approaches have yet to be validated, the evolution of
CNS drug delivery methods and rapid advances in RNA-
based therapeutics, including the advent of RNA aptamers
(RNA molecules engineered to bind with high aﬃnity to
speci�c molecular targets such as small molecules, pro-
teins, and nucleic acids), suggest that such strategies are
now possible [100]. Future therapies may also be designed
to target factors that serve as key modulators of CNS-
speci�c epigenetic events and thereby promote neural cell-
and tissue selective epigenetic reprogramming. For example,
these strategies may use novel agents that activate or inhibit
special AT-rich sequence-binding protein 2 (SATB2), the
repressor element-1 silencing transcription factor/neuron
restrictive silencing factor (REST/NRSF), and the corepres-
sor for element-1-silencing transcription factor (CoREST).
As an environmentally sensitive regulator of neuronal cell
fate decisions during development [101], SATB2 modulates
neuronal gene expression by promoting coordinate regula-
tion of multiple genes on diﬀerent chromosomes involved
in functionally integrated gene networks. ese molecular
processes involve dynamic reorganization of the nuclear
architecture to allow a seamless link between transcriptional
and posttranscriptional processing events and associated
RNA quality control mechanisms. SATB2 is also associated
with a regulatory lncRNA that is coexpressed with SATB2
[102]. ese observations suggest that therapeutic agents
targeting SATB2or its associated lncRNA could lead to
dynamic reprogramming of neuronal gene expression and
even neural cell identityand patterns of neural connectivity
that is essential for neural regeneration. REST and CoREST
are critical epigenetic factors that mediate predominantly
site-speci�c gene repression, gene activation, and long-term
gene silencing for a large spectrum of genes involved in
neural development, homeostasis, and plasticity, including
but not limited to those that encode growth factors, axon
guidance cues, ion channels, neurotransmitter receptors,
synaptic vesicle proteins, components of the cytoskeleton,
and elements of the extracellular matrix [103].
In addition, REST and CoREST modulate the expres-
sion of several classes of ncRNAs, including miRNAs and
lncRNAs.esemolecules act as dynamicmodular platforms
for the recruitment of a broad array of epigenetic factors to
neural gene loci in which they orchestrate site-speci�c and
genome-wide chromatin remodelling. One of the molecular
mechanisms that underlie cell death aer transient global
ischemia is REST dependent repression of the GluR2 subunit
and 𝜇𝜇 opioid receptor 1 [104, 105]. REST also regulates the
expression of a signi�cant number of the miRNAs that are
diﬀerentially expressed aer cerebral ischemia [52]. ese
observations suggest that therapeutic targeting of REST and
CoREST may have signi�cant eﬀects on highly integrated
epigenetic regulatory mechanisms that could promote repro-
gramming of neural cells to enhance neural regeneration
in stroke by recapitulating developmental events responsible
for establishing and remodelling neural cell identity and
neural network connectivity. Additional treatment strategies
may also be developed to �ne-tune epigenetic mechanisms
that mediate RNA modi�cations and traﬃcking within cells.
Among the more salient molecular targets may be regulatory
ncRNAs (e.g.,miRNAs and lncRNAs), RNAbinding proteins,
and cytoskeletal proteins (e.g., dyneins and kinesins) that
have prominent roles in a diverse array of processes that are
under epigenetic regulation, including alternative splicing;
editing; nuclear export; stabilization; temporal, spatial, and
activity-dependent localization; and translation of RNAs. For
example, rationally designed small molecules that bind to
miRNAs and modulate their activity are now under early
stage development, and these agents may speci�cally be
designed to target miRNAs that are deregulated in stroke
[106]. Furthermore, novel therapies may act by selectively
in�uencing the composition of complexes that carrymRNAs,
ncRNAs, proteins, and other functionally related factors.
ese structures, referred to as RNA operons,play key roles
in axodendritic transport and mediate local mRNA transla-
tion and synaptic plasticity [107]. Higher-order regulatory
mechanisms coordinate the dynamics of interrelated RNA
operons by modulating their individual components, the
kinetics of anterograde and retrograde axodendritic transport
and activity-dependent deployment and function of neuronal
RNAs. ese mechanisms are termed RNA regulons. In
postischemic neurons, vulnerability to cell death is associated
with pathological alterations in RNA operon and regulon
dynamics and stress responses that lead to translational [108].
ese observations imply that manipulating RNA posttran-
scriptional processingmay be useful in postischemic neurons
to promote cellular reprogramming and to selectively activate
responses that favorneuronal survival and the maintenance
of neural network integrity. Furthermore, RNA operons and
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regulons are implicated in bidirectional axodendritic trans-
port responsible for relaying RNA editing events from the
synapse to the nucleus for DNA recoding within postmitotic
neurons. Because these processes are implicated in multi-
generational inheritance, therapeutic interventions targeting
RNA editing events and associated recoding of the neuronal
genome may be implemented to directly alter stroke risk
even in future generations. Epigenetic mechanisms are also
involved in regulating cell-cell communication, including
the active transport of RNAs between adjacent nerve cells
through multiple signalling pathways, to more distant sites
within the same tissue, to other organ systems through
blood-borne routes, and even back to the germline; these
processes may represent novel targets for future therapeutic
initiatives [109]. Speci�c transmembrane proteins required
for the systemic spread of RNA interference are expressed in
the adult brain preferentially in areas associated with learn-
ing and memory. Moreover, microvesicles (i.e., exosomes)
containing mRNAs and ncRNAs are produced by neural
cells and secreted locally and into the peripheralcirculation
[110]. ese microvesicles may be responsible for cell-cell
communication through local and more long distance inter-
cellular RNA transfer because they express cell recognition
molecules on their surfaces for selective targeting and uptake
into recipient cells, in which mRNAs may be translated and
ncRNAs may exert their regulatory eﬀects. Modulation of
microvesicle composition and transport pathways may serve
as novel targets for regulating anterograde and retrograde
signalling across synapses, reinforcing local and long-range
neural network connectivity, and signalling to other organ
systems (i.e., the immune system) that may play seminal
roles in the pathogenesis and evolution of stroke syndromes
and associated co-morbidities. As epigenetic processes begin
to reveal the many previously hidden layers of functional
information embedded within the genome, many future
strategies can be envisioned that exploit these processes to
develop novel therapies. In fact, the epigenome provides
multiple layers of contextual controls that are intricately
interlaced and potentially modi�able, and a single epige-
netic intervention may even have a cascade of eﬀects on
many interrelated processes, including those that may be
important for circumventing the pathogenesis and sequelae
of stroke. For example, the DNA double helix itself has
the potential to form alternative structural conformations
with unique epigenetic properties that can be harnessed for
the treatment of stroke. Indeed, when the neuroprotective
cytokine, colony-stimulating factor 1, is activated by the
BRG1 chromatin-remodeling enzyme, a le-handed DNA
stereoisomer referred to as a Z-DNA structurecan be found
in the region actively being transcribed [111]. e formation
of Z-DNA stereoisomers can, in turn, modulate a range of
processes responsible for �ne-tuning transcriptional events,
regulating chromatin architecture, and promoting speci�c
forms of RNA editing [112]. us, understanding complex
epigenetic mechanisms and their complementary roles in
mediating CNS functions, both in health and in disease,
is important for developing next-generation technologies to
dynamically reprogram neural cells for treatment of complex
neurological disease states, including stroke [61].
12. Final Conclusions
Studies of epigenetic mechanisms in stroke are in their
infancy but oﬀer great promise for better understanding of
stroke pathology and the potential viability of new strategies
for its treatment. Correspondingly, inhibitors of histone
modi�cation have been suggested to be neuroprotective in
animal models of cerebral ischemia and intracranial haemor-
rhage. In turn, miRNAs have been shown to play diverse roles
in neuronal, glial, and endothelia responses to stroke. In addi-
tion, miRNAs have been suggested to regulate the eﬀects of
ischemia on aquaporin expression and function and in some
cases may be neuroprotective. miRNAsmay also help explain
gender-based diﬀerences in responses to cerebral ischemia.
RNA editing, a related epigenetic mechanism that is partly
responsible for generating the exquisite degrees of environ-
mental responsiveness and molecular diversity. In addition,
the development of future therapeutic strategies for locus-
speci�c and genome-wide regulation of genes and functional
gene networks through themodulation of RNA transcription,
posttranscriptional RNA processing (e.g., RNA modi�ca-
tions, quality control, intracellular traﬃcking, and local and
long distance intercellular transport), and RNA translation.
ese novel approaches for neural cell- and tissue-selective
reprogramming of epigenetic regulatory mechanisms are
likely to promote more eﬀective neuroprotective and neural
regenerative responses for safeguarding and even restoring
central nervous system function. Data accumulated to date
strongly suggest that further studies of these mechanisms are
well justi�ed and that future publications resulting from these
studies are worthy of careful attention.
References
[1] S. T. Carmichael, “Translating the frontiers of brain repair to
treatments: starting not to break the rules,” Neurobiology of
Disease, vol. 37, no. 2, pp. 237–242, 2010.
[2] J. J. Ohab, S. Fleming, A. Blesch, and S. T. Carmichael, “A
neurovascular niche for neurogenesis aer stroke,” Journal of
Neuroscience, vol. 26, no. 50, pp. 13007–13016, 2006.
[3] S. D. Giovanni, “Molecular targets for axon regeneration: focus
on the intrinsic pathways,” Expert Opinion on erapeutic
Targets, vol. 13, no. 12, pp. 1387–1398, 2009.
[4] M. Slevin, L. Badimon, M. Grau-Olivares et al., “Combining
nanotechnology with current biomedical knowledge for the
vascular imaging and treatment of atherosclerosis,” Molecular
BioSystems, vol. 6, no. 3, pp. 444–450, 2010.
[5] L. I. Benowitz and S. T.Carmichael, “Promoting axonal rewiring
to improve outcome aer stroke,” Neurobiology of Disease, vol.
37, no. 2, pp. 259–266, 2010.
[6] S. H. Kreisel, M. G. Hennerici, and H. Bäzner, “Pathophys-
iology of stroke rehabilitation: the natural course of clinical
recovery, use-dependent plasticity and rehabilitative outcome,”
Cerebrovascular Diseases, vol. 23, pp. 243–255, 2007.
[7] D. B. Hier, J. Mondlock, and L. R. Caplan, “Behavioral abnor-
malities aer right hemisphere stroke,”Neurology, vol. 33, no. 3,
pp. 337–344, 1983.
[8] M. L. Kauhanen, J. T. Korpelainen, P. Hiltunen et al., “Aphasia,
depression, and non-verbal cognitive impairment in ischaemic
10 Stroke Research and Treatment
stroke,” Cerebrovascular Diseases, vol. 10, no. 6, pp. 455–461,
2000.
[9] S. T. Carmichael, “Cellular andmolecularmechanisms of neural
repair aer stroke: making waves,” Annals of Neurology, vol. 59,
no. 5, pp. 735–742, 2006.
[10] L. I. Benowitz and S. T. Carmichael, “Promoting axonal rewiring
to improve outcome aer stroke,” Neurobiology of Disease, vol.
37, no. 2, pp. 259–266, 2010.
[11] P. Chen, D. E. Goldberg, B. Kolb, M. Lanser, and L. I. Benowitz,
“Inosine induces axonal rewiring and improves behavioral
outcome aer stroke,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 99, no. 13, pp.
9031–9036, 2002.
[12] C. M. Papadopoulos, S. Y. Tsai, T. Alsbiei, T. E. O’Brien,
M. E. Schwab, and G. L. Kartje, “Functional recovery and
neuroanatomical plasticity following middle cerebral artery
occlusion and IN-1 antibody treatment in the adult rat,” Annals
of Neurology, vol. 51, no. 4, pp. 433–441, 2002.
[13] J. Raber, Y. Fan, Y. Matsumori et al., “Irradiation attenu-
ates neurogenesis and exacerbates ischemia-induced de�cits,”
Annals of Neurology, vol. 55, no. 3, pp. 381–389, 2004.
[14] J. Krupinski, J. Kaluza, P. Kumar, M. Wang, and S. Kumar,
“Prognostic value of blood vessel density in ischaemic stroke,”
e Lancet, vol. 342, no. 8873, article 742, 1993.
[15] Z. G. Zhang and M. Chopp, “Neurorestorative therapies for
stroke: underlying mechanisms and translation to the clinic,”
e Lancet Neurology, vol. 8, no. 5, pp. 491–500, 2009.
[16] T. M. Bliss, R. H. Andres, and G. K. Steinberg, “Erratum
to Optimizing the success of cell transplantation therapy for
stroke,” Neurobiology of Disease, vol. 38, no. 3, p. 495, 2010.
[17] W. Pearce, “Epigenetics: an expanding new piece of the stroke
puzzle,” Translational Stroke Research, vol. 2, pp. 243–247, 2011.
[18] D. Botstein and N. Risch, “Discovering genotypes underlying
humanphenotypes: past successes formendelian disease, future
approaches for complex disease,” Nature Genetics, vol. 33, pp.
228–237, 2003.
[19] P. C. Ng and E. F. Kirkness, “Whole genome sequencing,”
Methods in Molecular Biology, vol. 628, pp. 215–226, 2010.
[20] M. B. Lanktree, M. Dichgans, and R. A. Hegele, “Advances in
genomic analysis of stroke: what have we learned and where are
we headed?” Stroke, vol. 41, no. 4, pp. 825–832, 2010.
[21] G. Marnellos, “High-throughput SNP analysis for genetic
association studies,” Current Opinion in Drug Discovery and
Development, vol. 6, pp. 317–321, 2003.
[22] J. F. Meschia, B. B. Worrall, and S. S. Rich, “Genetic suscepti-
bility to ischemic stroke,” Nature Reviews Neurology, vol. 7, pp.
369–378, 2011.
[23] B. Glaser, “Genetic analysis of complex disease—a roadmap
to understanding or a colossal waste of money,” Pediatric
Endocrinology Reviews, vol. 7, no. 3, pp. 258–265, 2010.
[24] R. Jaenisch and A. Bird, “Epigenetic regulation of gene expres-
sion: how the genome integrates intrinsic and environmental
signals,” Nature Genetics, vol. 33, pp. 245–254, 2003.
[25] J. P. Hamilton, “Epigenetics: principles and practice,” Digestive
Diseases, vol. 29, pp. 130–135, 2011.
[26] E. Ballestar, “An introduction to epigenetics,” Advances in
Experimental Medicine and Biology, vol. 711, pp. 1–11, 2011.
[27] K. Felekkis, E. Touvana, C. Stefanou, and C. Deltas, “MicroR-
NAs: a newly described class of encoded molecules that play
a role in health and disease,” Hippokratia, vol. 14, no. 4, pp.
236–240, 2010.
[28] Z. W. Pan, Y. J. Lu, and B. F. Yang, “MicroRNAs: a novel class of
potential therapeutic targets for cardiovascular diseases,” Acta
Pharmacologica Sinica, vol. 31, no. 1, pp. 1–9, 2010.
[29] N. Liu and E. N. Olson, “MicroRNA regulatory networks in
cardiovascular development,” Developmental Cell, vol. 18, no.
4, pp. 510–525, 2010.
[30] Y. Cheng and C. Zhang, “MicroRNA-21 in cardiovascular
disease,” Journal of Cardiovascular Translational Research, vol.
3, pp. 251–255, 2010.
[31] E. M. Small and E. N. Olson, “Pervasive roles of microRNAs in
cardiovascular biology,”Nature, vol. 469, no. 7330, pp. 336–342,
2011.
[32] K. C. Chen, Y. S. Wang, C. Y. Hu et al., “OxLDL up-regulates
microRNA-29b, leading to epigenetic modi�cations of MMP-
2/MMP-9 genes: a novel mechanism for cardiovascular dis-
eases,” FASEB Journal, vol. 25, no. 5, pp. 1718–1728, 2011.
[33] M. Han, J. Toli, and M. Abdellatif, “MicroRNAs in the cardio-
vascular system,” Current Opinion in Cardiology, vol. 26, no. 3,
pp. 181–189, 2011.
[34] O. Khorram, G. Han, R. Bagherpour et al., “Eﬀect of maternal
undernutrition on vascular expression of micro and messenger
RNA in newborn and aging oﬀspring,” American Journal of
Physiology, vol. 298, no. 5, pp. R1366–R1374, 2010.
[35] C. Van Solingen, L. Seghers, R. Bijkerk et al., “Antagomir-
mediated silencing of endothelial cell speci�c microRNA-126
impairs ischemia-induced angiogenesis,” Journal of Cellular and
Molecular Medicine, vol. 13, no. 8, pp. 1577–1585, 2009.
[36] Y. Ye, Z. Hu, Y. Lin, C. Zhang, and J. R. Perez-Polo, “Downreg-
ulation of microRNA-29 by antisense inhibitors and a PPAR-
𝛾𝛾agonist protects against myocardial ischaemia-reperfusion
injury,” Cardiovascular Research, vol. 87, no. 3, pp. 535–544,
2010.
[37] J. A. Nickerson, G. Krochmalnic, K. M. Wan, and S. Penman,
“Chromatin architecture and nuclear RNA,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 86, no. 1, pp. 177–181, 1989.
[38] A. Rodríguez-Campos and F. Azorín, “RNA is an integral
component of chromatin that contributes to its structural
organization,” PLoS ONE, vol. 2, no. 11, Article ID e1182, 2007.
[39] J. S. Mattick, “A new paradigm for developmental biology,”
Journal of Experimental Biology, vol. 210, no. 9, pp. 1526–1547,
2007.
[40] P. K. Yang and M. I. Kuroda, “Noncoding RNAs and intranu-
clear positioning in monoallelic gene expression,” Cell, vol. 128,
no. 4, pp. 777–786, 2007.
[41] H. L. Ashe, J. Monks, M. Wijgerde, P. Fraser, and N. J.
Proudfoot, “Intergenic transcription and transinduction of the
human 𝛽𝛽-globin locus,”Genes and Development, vol. 11, no. 19,
pp. 2494–2509, 1997.
[42] I. Abarrategui and M. S. Krangel, “Noncoding transcription
controls downstream promoters to regulate T-cell receptor 𝛼𝛼
recombination,” EMBO Journal, vol. 26, no. 20, pp. 4380–4390,
2007.
[43] J. C. Peng and G. H. Karpen, “H3K9 methylation and RNA
interference regulate nucleolar organization and repeated DNA
stability,” Nature Cell Biology, vol. 9, no. 1, pp. 25–35, 2007.
[44] M. Nowacki, V. Vijayan, Y. Zhou, K. Schotanus, T. G. Doak, and
L. F. Landweber, “RNA-mediated epigenetic programming of a
genome-rearrangement pathway,”Nature, vol. 451, no. 7175, pp.
153–158, 2008.
Stroke Research and Treatment 11
[45] S. Schoener and M. A. Blasco, “Developmentally regulated
transcription of mammalian telomeres by DNA-dependent
RNA polymerase II,” Nature Cell Biology, vol. 10, no. 2, pp.
228–236, 2008.
[46] C. M. Azzalin, P. Reichenbach, L. Khoriauli, E. Giulotto,
and J. Lingner, “Telomeric repeat-containing RNA and RNA
surveillance factors at mammalian chromosome ends,” Science,
vol. 318, no. 5851, pp. 798–801, 2007.
[47] N. Xu, M. E. Donohoe, S. S. Silva, and J. T. Lee, “Evidence that
homologous X-chromosome pairing requires transcription and
Ctcf protein,” Nature Genetics, vol. 39, no. 11, pp. 1390–1396,
2007.
[48] L. F. Zhang, K. D. Huynh, and J. T. Lee, “Perinucleolar targeting
of the inactive X during S phase: evidence for a role in the
maintenance of silencing,” Cell, vol. 129, no. 4, pp. 693–706,
2007.
[49] P. P. Amaral, M. E. Dinger, T. R. Mercer, and J. S. Mattick, “e
eukaryotic genome as an RNA machine,” Science, vol. 319, no.
5871, pp. 1787–1789, 2008.
[50] L. Formisano, K. M. Noh, T. Miyawaki, T. Mashiko, M. V. L.
Bennett, and R. S. Zukin, “Ischemic insults promote epigenetic
reprogramming of𝜇𝜇 opioid receptor expression in hippocampal
neurons,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 104, no. 10, pp. 4170–4175, 2007.
[51] F. Sato, S. Tsuchiya, S. J. Meltzer, and K. Shimizu, “MicroRNAs
and epigenetics,” FEBS Journal, vol. 278, no. 10, pp. 1598–1609,
2011.
[52] A. Dharap, K. Bowen, R. Place, L. C. Li, and R. Vemuganti,
“Transient focal ischemia induces extensive temporal changes
in rat cerebral MicroRNAome,” Journal of Cerebral Blood Flow
and Metabolism, vol. 29, no. 4, pp. 675–687, 2009.
[53] F. E. Nicolas, H. Pais, F. Schwach et al., “Experimental identi�-
cation of microRNA-140 targets by silencing and overexpress-
ing miR-140,” RNA, vol. 14, no. 12, pp. 2513–2520, 2008.
[54] K. Jeyaseelan, K. Y. Lim, and A. Armugam, “MicroRNA
expression in the blood and brain of rats subjected to transient
focal ischemia by middle cerebral artery occlusion,” Stroke, vol.
39, no. 3, pp. 959–966, 2008.
[55] H. Xin, Y. Li, B. Buller et al., “Exosome-mediated transfer
of miR-133b from multipotent mesenchymal stromal cells to
neural cells contributes to neurite outgrowth,” Stem Cells, vol.
30, no. 7, pp. 1556–1564, 2012.
[56] X. Zhao, X. He, X. Han et al., “MicroRNA-mediated control
of oligodendrocyte diﬀerentiation,” Neuron, vol. 65, no. 5, pp.
612–626, 2010.
[57] T. R. Mercer, M. E. Dinger, and J. S. Mattick, “Long non-coding
RNAs: insights into functions,”Nature Reviews Genetics, vol. 10,
no. 3, pp. 155–159, 2009.
[58] T. R. Mercer, M. E. Dinger, J. Mariani, K. S. Kosik, M. F. Mehler,
and J. S. Mattick, “Noncoding RNAs in long-term memory
formation,” Neuroscientist, vol. 14, no. 5, pp. 434–445, 2008.
[59] J. Rashidian, G. Iyirhiaro, H. Aleyasin et al., “Multiple
cyclin-dependent kinases signals are critical mediators of
ischemia/hypoxic neuronal death in vitro and in vivo,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 102, no. 39, pp. 14080–14085, 2005.
[60] N. Ishii, K. Ozaki, H. Sato et al., “Identi�cation of a novel non-
coding RNA, MIAT, that confers risk of myocardial infarction,”
Journal of HumanGenetics, vol. 51, no. 12, pp. 1087–1099, 2006.
[61] I. A. Qureshi and M. F. Mehler, “e emerging role of
epigenetics in stroke: II. RNA regulatory circuitry,” Archives of
Neurology, vol. 67, no. 12, pp. 1435–1441, 2010.
[62] P. L. Peng, X. Zhong, W. Tu et al., “ADAR2-dependent RNA
editing of AMPA receptor subunit GluR2 determines vulner-
ability of neurons in forebrain ischemia,” Neuron, vol. 49, no. 5,
pp. 719–733, 2006.
[63] M. J. Blow, R. J. Grocock, S. van Dongen et al., “RNA editing of
human microRNAs,” Genome Biology, vol. 7, no. 4, article R27,
2006.
[64] Y. Kawahara, B. Zinshteyn, T. P. Chendrimada, R. Shiekhattar,
and K. Nishikura, “RNA editing of the microRNA-151 pre-
cursor blocks cleavage by the Dicer—TRBP complex,” EMBO
Reports, vol. 8, no. 8, pp. 763–769, 2007.
[65] V. Shani, Y. Bromberg, O. Sperling, and E. Zoref-Shani,
“Involvement of Src tyrosine kinases (SFKs) and of focal adhe-
sion kinase (FAK) in the injurious mechanism in rat primary
neuronal cultures exposed to chemical ischemia,” Journal of
Molecular Neuroscience, vol. 37, no. 1, pp. 50–59, 2009.
[66] A. Selvamani, P. Sathyan, R. Miranda, and F. Sohrabji, “An
antagomir to MicroRNA Let7f promotes neuroprotection in an
ischemic stroke model,” PLoS ONE, vol. 7, no. 2, Article ID
e32662.
[67] S. G. Conticello, “e AID/APOBEC family of nucleic acid
mutators,” Genome Biology, vol. 9, no. 6, article 229, 2008.
[68] K. Silander, M. Alanne, K. Kristiansson et al., “Gender diﬀer-
ences in genetic risk pro�les for cardiovascular disease,” PLoS
ONE, vol. 3, no. 10, Article ID e3615, 2008.
[69] Y. J.Wang, X.Wang, H. Zhang et al., “Expression and regulation
of antiviral protein APOBEC3G in human neuronal cells,”
Journal of Neuroimmunology, vol. 206, no. 1-2, pp. 14–21, 2009.
[70] J. S.Mattick andM. F.Mehler, “RNA editing, DNA recoding and
the evolution of human cognition,” Trends in Neurosciences, vol.
31, no. 5, pp. 227–233, 2008.
[71] J. A. Watson, C. J. Watson, A. Mccann, and J. Baugh, “Epige-
netics, the epicenter of the hypoxic response,” Epigenetics, vol.
5, no. 4, pp. 293–296, 2010.
[72] N. Sang and S. Chen, “Histone deacetylase inhibitors: the
epigenetic therapeutics that repress hypoxia-inducible factors,”
Journal of Biomedicine and Biotechnology, vol. 2011, Article ID
197946, 2011.
[73] S. Biswas, S. Roy, J. Banerjee et al., “Hypoxia inducible micro-
RNA 210 attenuates keratinocyte proliferation and impairs
closure in a murine model of ischemic wounds,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 107, no. 15, pp. 6976–6981, 2010.
[74] S. Y. Chan and J. Loscalzo, “MicroRNA-210: a unique and
pleiotropic hypoxamir,” Cell Cycle, vol. 9, no. 6, pp. 1072–1083,
2010.
[75] J. A. Saugstad, “MicroRNAs as eﬀectors of brain function with
roles in ischemia and injury, neuroprotection, andneurodegen-
eration,” Journal of Cerebral Blood Flow & Metabolism, vol. 30,
pp. 1564–1576, 2010.
[76] C. H. Hsieh, J. C. Jeng, S. F. Jeng, C. J. Wu, T. H. Lu, P. C. Liliang
et al., “MicroRNA pro�ling in ischemic injury of the gracilis
muscle in rats,” BMC Musculoskeletal Disorders, vol. 11, article
123, 2010.
[77] C. Stowell, L. Wang, B. Arbogast et al., “Retinal proteomic
changes under diﬀerent ischemic conditions—Implication of
an epigenetic regulatory mechanism,” International Journal of
Physiology, Pathophysiology and Pharmacology, vol. 2, no. 2, pp.
148–160, 2010.
12 Stroke Research and Treatment
[78] P. Fasanaro, S. Greco,M. Ivan,M. C. Capogrossi, and F.Martelli,
“microRNA: emerging therapeutic targets in acute ischemic
diseases,” Pharmacology and erapeutics, vol. 125, no. 1, pp.
92–104, 2010.
[79] C. Yin, F. N. Salloum, and R. C. Kukreja, “A novel role of
microRNA in late preconditioning: upregulation of endothelial
nitric oxide synthase and heat shock protein 70,” Circulation
Research, vol. 104, no. 5, pp. 572–575, 2009.
[80] H. W. Kim, H. K. Haider, S. Jiang, and M. Ashraf, “Ischemic
preconditioning augments survival of stem cells via miR-210
expression by targeting caspase-8-associated protein 2,” Journal
of Biological Chemistry, vol. 284, no. 48, pp. 33161–33168, 2009.
[81] T. A. Lusardi, C. D. Farr, C. L. Faulkner et al., “Ischemic
preconditioning regulates expression of microRNAs and a
predicted target, MeCP2, in mouse cortex,” Journal of Cerebral
Blood Flow and Metabolism, vol. 30, no. 4, pp. 744–756, 2010.
[82] Y. Cheng, P. Zhu, J. Yang et al., “Ischaemic preconditioning-
regulated miR-21 protects heart against ischaemia/reperfusion
injury via anti-apoptosis through its target PDCD4,”Cardiovas-
cular Research, vol. 87, no. 3, pp. 431–439, 2010.
[83] A. M. Jose and C. P. Hunter, “Transport of sequence-speci�c
RNA interference information between cells,”Annual Review of
Genetics, vol. 41, pp. 305–330, 2007.
[84] G. Faraco, T. Pancani, L. Formentini et al., “Pharmacological
inhibition of histone deacetylases by suberoylanilide hydrox-
amic acid speci�cally alters gene expression and reduces
ischemic injury in the mouse brain,” Molecular Pharmacology,
vol. 70, no. 6, pp. 1876–1884, 2006.
[85] Y. Takami, H. Nakagami, R. Morishita et al., “Ubiquitin
carboxyl-terminal hydrolase L1, a novel deubiquitinating
enzyme in the vasculature, attenuates NF-𝜅𝜅B activation,” Arte-
riosclerosis, rombosis, and Vascular Biology, vol. 27, no. 10,
pp. 2184–2190, 2007.
[86] R. Setsuie and K. Wada, “e functions of UCH-L1 and its
relation to neurodegenerative diseases,” Neurochemistry Inter-
national, vol. 51, no. 2–4, pp. 105–111, 2007.
[87] Y. C. Lin, J. H. Lin, C. W. Chou, Y. F. Chang, S. H. Yeh,
and C. C. Chen, “Statins increase p21 through inhibition of
histone deacetylase activity and release of promoter-associated
HDAC1/2,”Cancer Research, vol. 68, no. 7, pp. 2375–2383, 2008.
[88] A. Dharap, K. Bowen, R. Place, L. C. Li, and R. Vemuganti,
“Transient focal ischemia induces extensive temporal changes
in rat cerebral MicroRNAome,” Journal of Cerebral Blood Flow
and Metabolism, vol. 29, no. 4, pp. 675–687, 2009.
[89] K. J. Yin, Z. Deng, H. Huang et al., “miR-497 regulates neuronal
death in mouse brain aer transient focal cerebral ischemia,”
Neurobiology of Disease, vol. 38, no. 1, pp. 17–26, 2010.
[90] J. A. Saugstad, “MicroRNAs as eﬀectors of brain function with
roles in ischemia and injury, neuroprotection, andneurodegen-
eration,” Journal of Cerebral Blood Flow andMetabolism, vol. 30,
no. 9, pp. 1564–1576, 2010.
[91] F. R. Sharp, G. C. Jickling, B. Stamova et al., “Molecular markers
andmechanisms of stroke: RNA studies of blood in animals and
humans,” Journal of Cerebral Blood Flow and Metabolism, vol.
31, pp. 1513–1531, 2011.
[92] P. Landry, I. Plante, D. L. Ouellet, M. P. Perron, G. Rousseau,
and P. Provost, “Existence of a microRNA pathway in anucleate
platelets,” Nature Structural and Molecular Biology, vol. 16, no.
9, pp. 961–966, 2009.
[93] K. Jeyaseelan, K. Y. Lim, and A. Armugam, “MicroRNA
expression in the blood and brain of rats subjected to transient
focal ischemia by middle cerebral artery occlusion,” Stroke, vol.
39, no. 3, pp. 959–966, 2008.
[94] K. S. Tan, A. Armugam, S. Sepramaniam et al., “Expression
pro�le of microRNAs in young stroke patients,” PLoS ONE, vol.
4, no. 11, Article ID e7689, 2009.
[95] D. Z. Liu, Y. Tian, B. P. Ander et al., “Brain and bloodmicroRNA
expression pro�ling of ischemic stroke, intracerebral hemor-
rhage, and kainate seizures,” Journal of Cerebral Blood Flow and
Metabolism, vol. 30, no. 1, pp. 92–101, 2010.
[96] R. Ji, Y. Cheng, J. Yue et al., “MicroRNA expression signature
and antisense-mediated depletion reveal an essential role of
MicroRNA in vascular neointimal lesion formation,” Circula-
tion Research, vol. 100, no. 11, pp. 1579–1588, 2007.
[97] Z. Zhang, X. Yang, S. Zhang, X. Ma, and J. Kong, “BNIP3
upregulation and EndoG translocation in delayed neuronal
death in stroke and in hypoxia,” Stroke, vol. 38, no. 5, pp.
1606–1613, 2007.
[98] T. Miyawaki, D. Ofengeim, K. M. Noh et al., “e endogenous
inhibitor of Akt, CTMP, is critical to ischemia-induced neu-
ronal death,” Nature Neuroscience, vol. 12, no. 5, pp. 618–626,
2009.
[99] M.Wood,H. Yin, andG.McClorey, “Modulating the expression
of disease genes with RNA-based therapy,” PLoS Genetics, vol. 3,
no. 6, Article ID e109, 2007.
[100] A. C. Yan and M. Levy, “Aptamers and aptamer targeted
delivery,” RNA Biology, vol. 6, no. 3, pp. 316–320, 2009.
[101] A. B. Gyorgy, M. Szemes, C. De Juan Romero, V. Tarabykin, and
D. V. Agoston, “SATB2 interacts with chromatin-remodeling
molecules in diﬀerentiating cortical neurons,” European Journal
of Neuroscience, vol. 27, no. 4, pp. 865–873, 2008.
[102] T. R. Mercer, M. E. Dinger, S. M. Sunkin, M. F. Mehler, and J.
S. Mattick, “Speci�c expression of long noncoding RNAs in the
mouse brain,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 105, no. 2, pp. 716–721, 2008.
[103] I. A. Qureshi andM. F.Mehler, “Regulation of non-coding RNA
networks in the nervous system-What’s the REST of the story?”
Neuroscience Letters, vol. 466, no. 2, pp. 73–80, 2009.
[104] A. Calderone, T. Jover, K. M. Noh et al., “Ischemic insults
derepress the gene silencer REST in neurons destined to die,”
Journal of Neuroscience, vol. 23, no. 6, pp. 2112–2121, 2003.
[105] L. Formisano, K. M. Noh, T. Miyawaki, T. Mashiko, M. V.
Bennett, and R. S. Zukin, “Ischemic insults promote epigenetic
reprogramming of 𝜇𝜇opioid receptor expression in hippocampal
neurons,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 104, no. 10, pp. 4170–4175, 2007.
[106] G. Shan, Y. Li, J. Zhang et al., “A small molecule enhances
RNA interference and promotesmicroRNA processing,”Nature
Biotechnology, vol. 26, no. 8, pp. 933–940, 2008.
[107] K. D. Mans�eld and J. D. Keene, “e ribonome: a dominant
force in co-ordinating gene expression,” Biology of the Cell, vol.
101, no. 3, pp. 169–181, 2009.
[108] D. J. DeGracia, J. T. Jamison, J. J. Szymanski, and M. K. Lewis,
“Translation arrest and ribonomics in post-ischemic brain:
layers and layers of players,” Journal of Neurochemistry, vol. 106,
no. 6, pp. 2288–2301, 2008.
[109] M. E. Dinger, T. R. Mercer, and J. S. Mattick, “RNAs as extracel-
lular signaling molecules,” Journal of Molecular Endocrinology,
vol. 40, no. 3-4, pp. 151–159, 2008.
Stroke Research and Treatment 13
[110] N. R. Smalheiser, “Exosomal transfer of proteins and RNAs at
synapses in the nervous system,” Biology Direct, vol. 2, article
35, 2007.
[111] H. Liu, N. Mulholland, H. Fu, and K. Zhao, “Cooperative activ-
ity of BRG1 and Z-DNA formation in chromatin remodeling,”
Molecular and Cellular Biology, vol. 26, no. 7, pp. 2550–2559,
2006.
[112] G. Wang and K. M. Vasquez, “Z-DNA, an active element in the
genome,” Frontiers in Bioscience, vol. 12, no. 12, pp. 4424–4438,
2007.
